%0 Journal Article
%T A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine
%A Fatima Motiwala
%A Hina Saeed
%A Hiren Patel
%A Muhammad Khalid Zafar
%A Namrata Jannareddy
%A Rikinkumar S. Patel
%A Zeeshan Mansuri
%J Archive of "Therapeutic Advances in Psychopharmacology".
%D 2019
%R 10.1177/2045125319847882
%X Recent reports state that the prevalence of tardive dyskinesia (TD) is 32% with typical antipsychotics, and 13% with atypical antipsychotics. Current evidence-based recommendations determine an unmet need for efficacious treatment of TD. This systematic review was planned to update the evidence for TD treatment, comparing two vesicular monoamine transporter 2 (VMAT2) inhibitors, deutetrabenazine (DBZ), and valbenazine (VBZ). Of 75 PubMed search results, 11 studies met the review criteria. Efficacy and tolerability were demonstrated in a series of randomized, placebo-controlled clinical trials in our review study, and the Abnormal Involuntary Movement Scale response of £¿50% reduction in score was robust for VBZ 80£¿mg/day in short-term and long-term studies. On the contrary, DBZ was equally efficacious at 12£¿mg twice daily, but additional information about long-term efficacy and persistence of effect is needed
%K clinical trial
%K deutetrabenazine
%K psychopharmacology review
%K tardive dyskinesia
%K valbenazine
%K VMAT2 inhibitor
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535739/